Literature DB >> 35583896

The Course of General Cognitive Ability in Individuals With Psychotic Disorders.

Katherine Jonas1, Wenxuan Lian2, Jennifer Callahan3, Camilo J Ruggero3, Sean Clouston4, Avraham Reichenberg5, Gabrielle A Carlson6, Evelyn J Bromet1, Roman Kotov1.   

Abstract

Importance: Schizophrenia is associated with major cognitive deficits and has been conceptualized as both a neurodevelopmental and a neurodegenerative disorder. However, when deficits develop and how they change over the course of illness is uncertain. Objective: To trace cognition from elementary school to old age to test neurodevelopmental and neurodegenerative theories of psychotic disorders. Design, Setting, and Participants: Data were taken from the Suffolk County Mental Health Project, a first-admission longitudinal cohort study of individuals with psychotic disorders. Participants were recruited from all 12 inpatient psychiatric facilities in Suffolk County, New York. This analysis concerns the 428 participants with at least 2 estimates of general cognitive ability. Data were collected between September 1989 and October 2019, and data were analyzed from January 2020 to October 2021. Exposures: Psychiatric hospitalization for psychosis. Main Outcomes and Measures: Preadmission cognitive scores were extracted from school and medical records. Postonset cognitive scores were based on neuropsychological testing at 6-month, 24-month, 20-year, and 25-year follow-ups.
Results: Of the 428 included individuals (212 with schizophrenia and 216 with other psychotic disorders), 254 (59.6%) were male, and the mean (SD) age at psychosis onset was 27 (9) years. Three phases of cognitive change were observed: normative, declining, and deteriorating. In the first phase, cognition was stable. Fourteen years before psychosis onset, those with schizophrenia began to experience cognitive decline at a rate of 0.35 intelligence quotient (IQ) points per year (95% CI, 0.29-0.42; P < .001), a significantly faster decline than those with other psychotic disorders (0.15 IQ points per year; 95% CI, 0.08-0.22, P < .001). At 22 years after onset, both groups declined at a rate of 0.59 IQ points per year (95% CI, 0.25-0.94; P < .001). Conclusions and Relevance: In this cohort study, cognitive trajectories in schizophrenia were consistent with both a neurodevelopmental and neurodegenerative pattern, resulting in a loss of 16 IQ points over the period of observation. Cognitive decline began long prior to psychosis onset, suggesting the window for primary prevention is earlier than previously thought. A window for secondary prevention emerges in the third decade of illness, when cognitive declines accelerate in individuals with schizophrenia and other psychotic disorders.

Entities:  

Mesh:

Year:  2022        PMID: 35583896      PMCID: PMC9118026          DOI: 10.1001/jamapsychiatry.2022.1142

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   25.911


  49 in total

1.  The relation of the trail making test to organic brain damage.

Authors:  R M REITAN
Journal:  J Consult Psychol       Date:  1955-10

Review 2.  The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.

Authors:  Lynn E DeLisi
Journal:  Schizophr Bull       Date:  2008-02-08       Impact factor: 9.306

3.  Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Robert R Bies; Takayuki Abe; Ariel Graff-Guerrero; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2013-07-01       Impact factor: 9.306

4.  Diagnostic shifts during the decade following first admission for psychosis.

Authors:  Evelyn J Bromet; Roman Kotov; Laura J Fochtmann; Gabrielle A Carlson; Marsha Tanenberg-Karant; Camilo Ruggero; Su-wei Chang
Journal:  Am J Psychiatry       Date:  2011-06-15       Impact factor: 18.112

5.  Longitudinal Cognitive Performance in Individuals at Ultrahigh Risk for Psychosis: A 10-year Follow-up.

Authors:  Kelly Allott; Stephen J Wood; Hok Pan Yuen; Alison R Yung; Barnaby Nelson; Warrick J Brewer; Daniela Spiliotacopoulos; Annie Bruxner; Magenta Simmons; Christina Broussard; Sumudu Mallawaarachchi; Christos Pantelis; Patrick D McGorry; Ashleigh Lin
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

Review 6.  Neurodevelopmental model of schizophrenia: update 2012.

Authors:  J L Rapoport; J N Giedd; N Gogtay
Journal:  Mol Psychiatry       Date:  2012-04-10       Impact factor: 15.992

Review 7.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

Authors:  M F Green; R S Kern; D L Braff; J Mintz
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

8.  Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia.

Authors:  Katherine G Jonas; Laura J Fochtmann; Greg Perlman; Yuan Tian; John M Kane; Evelyn J Bromet; Roman Kotov
Journal:  Am J Psychiatry       Date:  2020-02-12       Impact factor: 18.112

9.  Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis: A Systematic Review and Meta-analysis.

Authors:  Ana Catalan; Gonzalo Salazar de Pablo; Claudia Aymerich; Stefano Damiani; Veronica Sordi; Joaquim Radua; Dominic Oliver; Philip McGuire; Anthony J Giuliano; William S Stone; Paolo Fusar-Poli
Journal:  JAMA Psychiatry       Date:  2021-06-16       Impact factor: 25.911

Review 10.  Schizophrenia: a tale of two critical periods for prefrontal cortical development.

Authors:  L D Selemon; N Zecevic
Journal:  Transl Psychiatry       Date:  2015-08-18       Impact factor: 6.222

View more
  1 in total

1.  Premorbid adjustment associates with cognitive and functional deficits in individuals at ultra-high risk of psychosis.

Authors:  Julie Lundsgaard; Tina Dam Kristensen; Christina Wenneberg; Maja Gregersen; Merete Nordentoft; Louise Birkedal Glenthøj
Journal:  Schizophrenia (Heidelb)       Date:  2022-10-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.